FASENRA

Описание товара

About FASENRA

FASENRA is a prescription medication used to treat severe asthma in adults and children aged 12 years and older. It is also used to treat chronic rhinosinusitis with nasal polyps in adults. FASENRA contains the active ingredient benralizumab, a monoclonal antibody that targets and eliminates eosinophils, a type of white blood cell involved in inflammation.

Key Benefits & Uses

• Treats severe asthma in adults and children aged 12 years and older
• Treats chronic rhinosinusitis with nasal polyps in adults
• Reduces eosinophil levels, helping to control inflammation and symptoms

Active Ingredient & Action

Benralizumab, the active ingredient in FASENRA, is a humanized monoclonal antibody that binds to the interleukin-5 receptor alpha subunit (IL-5Rα) on the surface of eosinophils. This binding causes the eosinophils to be marked for destruction by the immune system, leading to a reduction in eosinophil levels and a decrease in inflammation.

Important Notes

FASENRA is administered via subcutaneous injection every 4 weeks. It is essential to follow the prescribed dosing schedule and to report any changes in symptoms or side effects to your healthcare provider. FASENRA may increase the risk of infections, including serious infections such as pneumonia. It is also essential to inform your healthcare provider of any pre-existing medical conditions, including liver or kidney disease, before starting treatment with FASENRA.